Our Blog
Follow:
A new step into precision medicine
Since the end of May 2019, around 40% of patients with HR+/HER2- breast cancer can count on a new drug developed by Novartis and approved by the FDA. This new development is another important step into the field of precision medicine. Piqray® is indeed specific to...
4bases launches a new website
After the renewal of our ISO13485:2016 certification in May, the entry of new products in our pipeline and the opening of new markets, the Swiss supplier of CE IVD certified genetic diagnostic tests 4bases launches today its new website. Concise but comprehensive, the...